Clinical Trial Update: Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS [Phase 4]

View source ↗

Summary

The Phase 4 clinical trial evaluating cognitive benefits of ozanimod in multiple sclerosis, including brain biomarker analyses, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Zeposia (ozanimod hydrochloride)

Snippet

Sponsor: The University of Texas at Dallas | Conditions: Multiple Sclerosis | Phase 4 | Status: WITHDRAWN